Imago BioSciences Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Imago BioSciences Inc
Access all reports
Imago BioSciences, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme used in the production of blood cells in the bone marrow. We are conducting clinical trials for bomedemstat which is being developed as a treatment for myeloproliferative neoplasms (MPNs).
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
IMGO
Country
🇺🇸 United States